SHC rejects pharma firm's pleas seeking hike in drug prices
The verdict, delivered by a division bench comprising Acting Chief Justice Muhammad Junaid Ghaffar and Justice Mohammad Abdur Rahman, had the core of the legal dispute originated from a pricing of three commonly used medicines including Brufen (tablet) 200mg, Brufen Suspension 120ml, and Thyronorm (Tablet) 125 mcg.
Abbott sought an annual MPR increase of up to 10 percent for the fiscal year 2023-24. The company's argument hinged on the historical categorization of these medicines as 'lower priced drugs' under Rule 10 of the Drug Pricing Policy, which traditionally entitled them to a CPI-linked increase of up to 10 percent. Abbott asserted that it had submitted the required calculations to DRAP on July 1, 2024, and that the authority's failure to issue a decision within the stipulated 30 days should, under Rule 7(2)(ii) of the policy, result in their self-determined revised prices being deemed approved and officially notified.
DRAP, represented by the Assistant Attorney General for the Federation of Pakistan, contested this position. The regulatory body asserted that the MRPs of these specific medicines had, over successive years of CPI-linked adjustments, gradually escalated and now surpassed the maximum thresholds prescribed for 'lower priced drugs' under Rule 10(1) of the policy. Consequently, DRAP had reclassified them as 'other drugs,' thereby capping their permissible annual increase at 7 percent instead of the 10 percent sought by Abbott.
This reclassification and DRAP's subsequent decision were upheld by its Appellate Board, compelling Abbott Laboratories to seek judicial intervention through the constitutional petitions, specifically challenging DRAP's order dated March 12, 2025, and previous orders from November 7, 2024, as 'illegal, unlawful, unconstitutional, without jurisdiction, malafide, and of no legal effect.'
The High Court, in its detailed judgment, rejected Abbott's argument for 'deemed notification' or 'deemed approval.' The court clarified that rules allow for the deemed issuance of revised MRPs only if the submitted calculations are 'in conformity with' and represent 'correct calculations' under the policy. Since Abbott's claim was predicated on categorizing the medicines as 'lower priced drugs' despite their MRPs having already crossed the officially notified thresholds, the court held that Abbott's calculations were not policy-compliant.
Addressing Abbott's contention that the same medicines were recognized as 'lower priced drugs' in the preceding year despite exceeding the threshold, the court stated that even if such a regulatory oversight occurred previously, it could not justify repeating the error. The court underlined the legal maxim that 'two wrongs do not make a right,' rejecting the notion that a past administrative lapse could serve as a binding precedent or justification for current policy violations.
The court also drew attention to a crucial procedural lapse by the Ministry of National Health Services, Regulations and Coordination. The judgment noted that under Rule 10(2) of the Drug Pricing Policy, the Ministry is legally obligated to revise the thresholds for lower-priced drugs annually in accordance with CPI changes. This statutory requirement, the court observed, had not been fulfilled, thereby indirectly contributing to pricing, however, because Abbott Laboratories had not directly challenged this specific omission in its petitions, the court refrained from issuing a definitive order on this matter due to jurisdictional limitations.
Nonetheless, the court acknowledged that the issue 'warrants attention' and granted Abbott Laboratories the liberty to pursue this concern independently before the Ministry or any other competent legal forum. The court directed that any such representation filed by Abbott in this regard must be decided upon by the respondent within 60 days.
The Sindh High Court found no merit in Abbott Laboratories' plea for a 10 percent price increase. It upheld the decisions of DRAP and its Appellate Board as 'legally correct,' given the undisputed fact that as of July 1, 2024, the MRPs of the disputed medicines had indeed exceeded the thresholds specified for lower-priced drugs, thereby disqualifying them from such categorization.
Copyright Business Recorder, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
5 hours ago
- Business Recorder
S&P 500, Nasdaq hover near record highs
NEW YORK: The benchmark S&P 500 and the Nasdaq hovered near record highs on Wednesday as investors were increasingly confident that the Federal Reserve could restart its monetary policy easing cycle next month. Signs that US tariffs on imports have not fully filtered into headline consumer prices came as a relief for investors this week as they scour for insights on the impact trade uncertainty has had on the economy. Despite data showing underlying price pressures were on the rise, markets also factored in recent weakness in the job market and a shake-up at the Federal Reserve as they leaned in favor of a potential dovish move by the central bank in September. Traders are now fully pricing in a 25 basis points interest rate cut, according to the CME's FedWatch Tool, up from 89.2% last week. The central bank last lowered borrowing costs in December. Treasury Secretary Scott Bessent also said he thought an aggressive half-point cut was possible given recent weak employment numbers. Stagflation 'was the first word that came to my mind when I saw this CPI report yesterday,' said Mark Hackett, chief market strategist at Nationwide, referring to Tuesday's data coming on the heels of a number of other reports pointing to a cooling economy. 'The slowdown that we're seeing is probably fairly temporary, at least at this point. So inflation is something that we're absolutely worried about because we saw that uptick.' At 12:18 p.m. ET, the Dow Jones Industrial Average rose 363.26 points, or 0.82%, to 44,821.52, the S&P 500 gained 9.34 points, or 0.15%, to 6,455.15 and the Nasdaq Composite advanced 15.77 points, or 0.07%, to 21,697.97. The blue-chip Dow was within 1% away from an all-time high and the Russell 2000 index, which tracks rate-sensitive small-cap companies, added 0.1.3% to hit a six-month high. Investors were also taking notice of other sectors following the recent tech-led rally in US stocks that have pushed valuations of the S&P 500 above long-term averages. Healthcare stocks, which have been beaten down for much of the year, led gains among the 11 S&P 500 sectors with a 1.4% rise, while the tech-heavy Nasdaq 100 index was marginally lower. Later in the day, investors will scrutinize remarks of a number of policymakers, especially Chicago Fed President Austan Goolsbee. CoreWeave, which is backed by Nvidia, slumped 17.6% after the AI data center operator reported a bigger-than-expected quarterly net loss. Eyes are also on developments surrounding the China revenue-sharing deal the US government signed with top chipmakers, which the White House said could be expanded to others in the sector. Paramount Skydance jumped 30%. The company won exclusive broadcasting rights to the Ultimate Fighting Championship for seven years earlier this week. In geopolitics, traders also were keen on a meeting between Trump and Russia's Vladimir Putin on the Ukraine conflict scheduled on Friday. Advancing issues outnumbered decliners by a 2.96-to-1 ratio on the NYSE and by a 2.28-to-1 ratio on the Nasdaq. The S&P 500 posted 37 new 52-week highs and two new lows, while the Nasdaq Composite recorded 131 new highs and 49 new lows.
Business Recorder
14 hours ago
- Business Recorder
TSX climbs to record peak on Fed rate cut hopes
Canada's main stock index scaled an all-time high on Wednesday, bolstered by ongoing optimism surrounding a September U.S. Federal Reserve interest rate cut. At 9:50 a.m. ET (1350 GMT), the Toronto Stock Exchange's S&P/TSX composite index was up 0.39% at 28,028.83 points. The move builds on the benchmark index's record close on Tuesday after the July CPI report from the U.S. suggested a limited impact of tariffs on prices and reinforced bets for the Federal Reserve rate cut in September. Traders have fully priced in a September rate cut and view at least two reductions by the end of 2025, according to the CME Group's FedWatch tool. 'People are focusing more on things like the U.S. interest rate cuts, Trump and Putin meeting on Friday, the U.S. either resolving or delaying some of their tariff threats,' said Colin Cieszynski, chief market strategist at SIA Wealth Management. 'We're seeing equity markets continue to do well, people remain confident the economy has held up, and inflation has not taken off as much as people thought.' TSX's consumer discretionary led the sectoral gains with a 1.7% jump, boosted by Gildan Activewear surging 12%, after the apparel manufacturer agreed to buy U.S. undergarments maker Hanesbrands for $2.2 billion. Materials climbed 0.7%, thanks to elevated gold and copper prices on the back of U.S. policy easing optimism. A solid earnings season, reduced trade tensions and expectations of policy easing have pulled global equities up from the April lows triggered by Trump's 'Liberation Day' tariffs. TSX is up over 13% this year, outperforming Wall Street's S&P 500's 10% rise. Markets are also bracing for a high-stakes meeting between U.S. President Donald Trump and Russian President Vladimir Putin on Friday to discuss a potential end to the war in Ukraine. At 13:30 ET, the Bank of Canada will release a summary of the monetary policy deliberations that went behind its July interest rate decision, when it kept rates unchanged.
Business Recorder
16 hours ago
- Business Recorder
Gulf bourses mixed on weaker corporate earnings, Fed rate cut hopes
Gulf equities closed mixed on Wednesday, with Dubai and Abu Dhabi stock markets falling, as a raft of corporate earnings weighed, while Qatar hit over two-year high after U.S. inflation data fueled bets for a September interest rate cut. A mild July CPI report from the U.S. suggested a limited impact of tariffs on prices, reinforcing bets for the Federal Reserve rate cut in September. Monetary policy shifts in the U.S. have a significant impact on Gulf markets, where most currencies are pegged to the dollar. The Qatari benchmark index jumped 1.9% to 11,635 and hit its highest level since December 2022, with almost all of its constituents posting gains. Qatar National Bank, the region's largest lender, advanced 2.9% and Qatar Islamic Bank climbed 3.8%. 'Stocks were buoyed by the positive sentiment globally as investors focused on a softer monetary policy in the U.S.,' said Milad Azar, market analyst at XTB MENA. Saudi Arabia's benchmark stock index eased 0.1%, dragged down by losses in real estate, consumer staples, health care and energy shares. Al Rajhi Bank shed 0.9% and Al Nahdi Medical slid 4.8%. Gulf shares mixed on corporate earnings Atheeb Telecom advanced 3.7%, after the telecom services provider said on Tuesday it was awarded a project by the Ministry of National Guard. The Abu Dhabi benchmark index fell for a sixth day, ending 0.1% lower. Abu Dhabi Ports dropped 3.2%, after the port operator's second-quarter profit declined 4% year-on-year, below market expectations. Alpha Data slipped 2.2%, as the technology services firm posted a 4.9% drop in second-quarter net profit. Dubai's benchmark stock index slipped 0.4%, pressured by losses in real estate, industry, utilities and finance. Tolls operator Salik dropped 1.9% and blue-chip developer Emaar Properties lost 1.7%. Amlak Finance closed as the worst performer on the index, dropping 3.7%, after the real estate financier posted a second-quarter net loss on Tuesday. Outside the Gulf, Egypt's blue-chip index was down 0.4%, pressured by a 6.2% drop in Qalaa Holdings and a 3.1% loss in Madinet Masr. Developer MASR posted an 11.9% decrease in half-year net profit on Tuesday. ---------------------------------------- SAUDI ARABIA down 0.1% to 10,763 KUWAIT up 0.7% to 9,346 QATAR rose 1.9% to 11,635 EGYPT down 0.4% to 35,856 BAHRAIN added 0.5% to 1,949 OMAN up 0.1% to 4,900 ABU DHABI down 0.1% to 10,283 DUBAI dropped 0.4% to 6,091 ----------------------------------------
